Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:103114rdf:typepubmed:Citationlld:pubmed
pubmed-article:103114lifeskim:mentionsumls-concept:C0242422lld:lifeskim
pubmed-article:103114lifeskim:mentionsumls-concept:C0018546lld:lifeskim
pubmed-article:103114lifeskim:mentionsumls-concept:C0031979lld:lifeskim
pubmed-article:103114pubmed:issue2lld:pubmed
pubmed-article:103114pubmed:dateCreated1979-2-21lld:pubmed
pubmed-article:103114pubmed:abstractTextThree groups of schizophrenic patients were treated with haloperidol, with a low dose of piribedil (a dopamine agonist), and with a combination of the two treatments, respectively. After a few days, all 7 patients treated with the drug combination showed marked rigidity and akinesia, while patients treated with haloperidol alone (4) and piribedil alone (4) showed either mild or no symptoms of parkinsonism. The drug combination induced mainly an akinetic-hypertonic syndrome, while tremors were absent or mild. The results suggest that low doses of the DA-agonist potentiate the extrapyramidal side effects of haloperidol by acting on self-inhibitory DA receptors, thereby blocking the compensatory increase in dopaminergic firing elicited by the neuroleptic agent.lld:pubmed
pubmed-article:103114pubmed:languageenglld:pubmed
pubmed-article:103114pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:103114pubmed:citationSubsetIMlld:pubmed
pubmed-article:103114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:103114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:103114pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:103114pubmed:statusMEDLINElld:pubmed
pubmed-article:103114pubmed:monthOctlld:pubmed
pubmed-article:103114pubmed:issn0033-3158lld:pubmed
pubmed-article:103114pubmed:authorpubmed-author:GessaG LGLlld:pubmed
pubmed-article:103114pubmed:authorpubmed-author:MangoniAAlld:pubmed
pubmed-article:103114pubmed:authorpubmed-author:CorsiniG UGUlld:pubmed
pubmed-article:103114pubmed:authorpubmed-author:Del ZompoMMlld:pubmed
pubmed-article:103114pubmed:authorpubmed-author:SpissuAAlld:pubmed
pubmed-article:103114pubmed:issnTypePrintlld:pubmed
pubmed-article:103114pubmed:day31lld:pubmed
pubmed-article:103114pubmed:volume59lld:pubmed
pubmed-article:103114pubmed:ownerNLMlld:pubmed
pubmed-article:103114pubmed:authorsCompleteYlld:pubmed
pubmed-article:103114pubmed:pagination139-41lld:pubmed
pubmed-article:103114pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-H...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-A...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-S...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-F...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-M...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-P...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-A...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-T...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-H...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-C...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-P...lld:pubmed
pubmed-article:103114pubmed:meshHeadingpubmed-meshheading:103114-P...lld:pubmed
pubmed-article:103114pubmed:year1978lld:pubmed
pubmed-article:103114pubmed:articleTitleParkinsonism by haloperidol and piribedil.lld:pubmed
pubmed-article:103114pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:103114pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:103114pubmed:publicationTypeRandomized Controlled Triallld:pubmed